XML 57 R18.htm IDEA: XBRL DOCUMENT
v3.25.1

License Agreements | 12 Months Ended
--- | ---
Dec. 31, 2024
License Agreements |
License Agreements | Note 7 – License Agreements We have entered into license agreements which allow us to develop, manufacture, and/or commercialize the following drug assets: Schedule of License Agreements
Licensor |  | Drug Asset |  | Agreement Date |  | Amendment Date
Elion Oncology, Inc. |  | NGC-Cap (PCS6422) |  | August 23, 2020 |  | May 17, 2022
Ocuphire Pharma, Inc. |  | NGC-Gem (PCS3117) |  | June 16, 2021 |  | N/A
Aposense, Ltd. |  | NGC-Iri (PCS11T) |  | May 24, 2020 |  | N/A
Yuhan Corporation |  | PCS12852 |  | August 19, 2020 |  | N/A
CoNCERT Pharmaceuticals, Inc. |  | PCS499 |  | March 19, 2018 |  | N/A
For more information, you should refer to the summaries described in the Business section of this Annual Report and the copies of such agreements, which have been filed as exhibits to this Annual Report.

X
- References No definition available. + Details
Name: | PCSA_DisclosureLicenseAgreementsAbstract
Namespace Prefix: | PCSA_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition License Agreement Disclosure [Text Block] + References No definition available. + Details
Name: | PCSA_LicenseAgreementDisclosureTextBlock
Namespace Prefix: | PCSA_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration